Fig. 1From: Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancerPlasma protein biomarkers upregulated after administration of low-dose cyclophosphamide (x axis) or JX-594 (y axis)Back to article page